Nektar Therapeutics announced amendments to its bylaws, including an increase in authorized common stock shares from 300 million to 390 million, effective June 6, 2025. Additionally, a reverse stock split at a ratio of one-for-fifteen will take effect on June 8, 2025, consolidating every fifteen shares into one. Trading on a split-adjusted basis will begin on June 9, 2025, under the existing symbol "NKTR" with a new CUSIP number.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.